SGX welcomes medical technology firm Biolidics to Catalist

Biolidics debuted at $0.265.

Medical technology firm Biolodics has joined the Singapore Exchange’s (SGX) Catalist board, an announcement revealed.

The firm focuses on developing cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for the treatment of cancer including diagnosis, prognosis, treatment selection and monitoring, the statement highlighted.

“With Biolidics’ novel patented technology to separate and enrich cancer cancer cells from blood, there is great potential for Biolidics’ chances to grow and successfully exploit the opportunities in the cancer diagnostics industry,” Biolidics’ CEO and executive director said in a statement.

Biolidics debuted at $0.265, according to SGX.

With a market capitalisation of approximately $68m, Biolidics’ listing brings the total number of companies listed on Catalist to 214 with a combined market capitalisation of more than $10b, SGX noted. The latest listing is expected to strengthen SGX’s healthcare cluster which comprises of 40 companies with a combined market capitalisation of more than $70b.

“Singapore houses one of the region’s biggest medical technology clusters and is at the forefront of many developments on the medical front,” Mohammed Nasser Ismail, SGX head of equity capital market (SME) and capital market development, said in a statement.